mRNA shouldn’t have a party affiliation

Cancer medicine had an extraordinary weekend in Madrid. At the European Society for Medical Oncology Congress, Amgen’s Imdelltra, added to AstraZeneca’s Imfinzi as maintenance therapy for extensive-stage small-cell lung cancer, cut the risk of death by 58%. Median survival rose from just under 13 months to a little over 21 months. Then came another landmark […]

Read it at Washington Examiner ↗

← Front page